Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyViva Health Firmagon (degarelix) Prior Auth Policy…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0044

    Firmagon (degarelix) coverage and prior authorization

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0044 alerts

    Get alerted when Policy IC-0044 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior authorization, dosing, and coverage criteria for Firmagon (degarelix) for treatment of prostate cancer for Viva Health members age 18 and older.

    Policy Summary
    PayerViva Health
    PolicyFirmagon (degarelix) coverage and prior authorization
    Policy CodePolicy IC-0044
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for Firmagon; initial approval is for 180 days and may be renewed every 180 days when renewal criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    240 mgstarting dose (one-time)
    80 mgmaintenance dose every 28 days
    180 daysinitial prior authorization duration
    J9155HCPCS billing code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    C61
    covered diagnosis code (prostate cancer)

    Coverage criteria for Firmagon (degarelix)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval for Prostate Cancer

    • Age: Member is at least 18 years of age
    • Indication: Prostate cancer per FDA-approved or compendia-recommended indications
    Dosing Limits: Starting dose 240 mg administered as two 120 mg subcutaneous injections for one dose; maintenance dose 80 mg subcutaneously every 28 days thereafter.

    Max units: 240 units for starting dose; 80 units every 28 days for maintenance.

    Continuation Therapy / Renewal

    Renewal approved when ALL of the following are met:

    Renewal Criteria: Member continues to meet the indication-specific criteria; disease response is demonstrated by stabilization or decrease in tumor size or spread; and absence of unacceptable toxicity from the drug.

    Examples of unacceptable toxicity include QT interval prolongation and severe hypersensitivity reactions.

    Renewal of prior authorization is contingent on evidence that the member continues to meet the indication-specific criteria and demonstrates disease response to treatment, defined as stabilization of disease or a decrease in tumor size or spread. Renewal will not be approved if there is evidence of unacceptable toxicity attributed to degarelix. Examples of such unacceptable toxicities explicitly cited in the policy include QT interval prolongation and severe hypersensitivity reactions.

    This policy limits coverage to the prostate cancer indications described in the document and supporting references. The policy does not include explicit statements authorizing coverage for other, non‑listed indications; therefore payor coverage is confined to the indicated prostate cancer diagnoses and the associated prior authorization criteria outlined in the policy.

    Billing and coding references

    Covered HCPCS CodesHCPCSCovered
    J9155Injection, degarelix, 1 mg; 1 billable unit = 1 mg
    Covered ICD-10 CodesICD-10Covered
    C61Malignant neoplasm of prostate
    Z85.46Personal history of malignant neoplasm of prostate
    NDC(s)NDC
    55566-8303-xxFirmagon 80 mg single-dose vial powder for injection Maintenance Dose Kit
    55566-8403-xxFirmagon 120 mg single-dose vials (2) powder for injection Starting Dose Kit

    What providers must do

    Prior Authorization

    Prior authorization duration and renewal

    Prior authorization is required. Initial approval is provided for 6 months (180 days) and may be renewed every 6 months (180 days) thereafter when renewal criteria are met.

    • Initial: prior authorization validity will be provided initially for 6 months (180 days).
    • Renewal: prior authorization validity may be renewed every 6 months (180 days) thereafter.
    Step Therapy

    Step therapy not required

    No step therapy (no required trials of alternative therapies) is specified in this policy.

    Clinical background

    Degarelix is a gonadotropin‑releasing hormone (GnRH) receptor antagonist used in the management of prostate cancer. The policy references the FDA‑approved product labeling and the NCCN Drugs & Biologics Compendium as supporting sources for the labeled indications and recommended use, including dosing and monitoring considerations.

    Referenced compendia and sources

    NCCN Compendium — policy reference
    Referenced resourceNCCN Drugs & Biologics Compendium (NCCN Compendium) cited as a supporting source for Degarelix (Firmagon).
    Purpose of citationSupports compendia-recommended indications for degarelix used in the policy.
    Access noteDocument states the NCCN Compendium was referenced with permission and accessed May 2026.
    How to verifySee NCCN.org for the most recent and complete version of the NCCN Drugs & Biologics Compendium referenced by the policy.
    Policy Summary
    PayerViva Health
    PolicyFirmagon (degarelix) coverage and prior authorization
    Policy CodePolicy IC-0044
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for Firmagon; initial approval is for 180 days and may be renewed every 180 days when renewal criteria are met.
    SourceLink
    On This Page
    Coverage criteria for Firmagon (degarelix)Billing and coding referencesWhat providers must doClinical backgroundReferenced compendia and sources
    Documentation Required

    Required documentation to support PA

    Include documentation of the covered diagnosis (ICD-10 C61 or Z85.46), the dosing administered tied to HCPCS J9155 units (J9155 = injection, degarelix, 1 mg; 1 billable unit = 1 mg), and the NDC when applicable (starting and maintenance kit NDCs).

    • Covered diagnosis codes: C61 (malignant neoplasm of prostate) or Z85.46 (personal history of malignant neoplasm of prostate).
    • HCPCS J9155 corresponds to degarelix dosing by mg (1 unit = 1 mg).
    • NDCs: 55566-8403-xx (starting dose kit) and 55566-8303-xx (maintenance dose kit).
    Denial Risk

    Denial risks and triggers

    Prior authorization may be denied if the member does not meet the age requirement (must be at least 18) or does not meet the indication criteria; utilization management considerations such as cost-driven PA requirements also apply.

    • Member must be at least 18 years of age.
    • Indication must be prostate cancer per FDA-approved or compendia-recommended indications.
    • Utilization management (e.g., cost considerations) is a factor in applying prior authorization.